AURKA
AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer.
Overview
Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localisation of NUMA1 and DCTN1 to the cell cortex during metaphase.
CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Cisplatin, Alisertib, Paclitaxel and Platinum Compound and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer.
- 1 · What it is
AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression.
- 3 · How drugs use it
No product in this corpus aims at AURKA yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:11393 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14965 (protein name, function text, keywords and locations (REST API)); CIViC gene AURKA (7 evidence items, 0 assertions, 3 variants; diseases: Oesophagus Adenocarcinoma, Lung Non-small Cell Carcinoma, Ovarian Carcinoma, Ovarian Serous Carcinoma, Oesophagus Squamous Cell Carcinoma and 1 more (GraphQL API, CC0))
Biology
Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localisation of NUMA1 and DCTN1 to the cell cortex during metaphase. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Phosphorylates MCRS1 which is required for MCRS1-mediated kinetochore fibre assembly and mitotic progression. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, spindle pole; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole; Cell projection, neuron projection (UniProt). Locus 20q13.2 (HGNC).
- Oesophageal cancer: CIViC evidence names this disease
- Ovarian cancer: CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 6 therapies; CIViC holds 7 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Cervical Adenocarcinoma.
Latest papers
topQuery for this target: (TITLE:"AURKA" OR ABSTRACT:"AURKA" OR TITLE:"aurora kinase A" OR ABSTRACT:"aurora kinase A" OR TITLE:"Aurora kinase A" OR ABSTRACT:"Aurora kinase A" OR TITLE:"AurA" OR ABSTRACT:"AurA" OR TITLE:"STK7" OR ABSTRACT:"STK7" OR TITLE:"ARK1" OR ABSTRACT:"ARK1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AURKA, not a curated reading list.